Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection

Max R. O'Donnell, Nesri Padayatchi, Amrita Daftary, Catherine Orrell, Kelly Elise Dooley, K. Rivet Amico, Gerald Friedland

Research output: Contribution to journalComment/debate

Abstract

Bedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved survival including in HIV patients with multidrug and extensively drug-resistant tuberculosis. In line with WHO recommendations, in South Africa and other low-income and middle-income settings, antiretroviral therapy is switched from generic fixed-dose combination efavirenz-containing regimens to twice-daily nevirapine with separate companion pills because of interactions between efavirenz and bedaquiline. Early data suggest a signal for low antiretroviral therapy adherence after this antiretroviral therapy switch. Mortality and other tuberculosis-specific benefits noted with bedaquiline treatment in multidrug and extensively drug-resistant tuberculosis HIV might be compromised by HIV viral failure, and emergent antiretroviral resistance. Programmatic responses, such as adherence support and dual pharmacovigilance, should be instituted; antiretroviral therapy initiation with fixed-dose combinations without bedaquiline drug interactions should be strongly considered.

Original languageEnglish (US)
Pages (from-to)e201-e204
JournalThe Lancet HIV
Volume6
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

bedaquiline
Multidrug-Resistant Tuberculosis
Coinfection
HIV Infections
efavirenz
Extensively Drug-Resistant Tuberculosis
HIV
Therapeutics
Pharmacovigilance
Nevirapine
South Africa
Drug Interactions
Tuberculosis

ASJC Scopus subject areas

  • Epidemiology
  • Immunology
  • Infectious Diseases
  • Virology

Cite this

O'Donnell, M. R., Padayatchi, N., Daftary, A., Orrell, C., Dooley, K. E., Rivet Amico, K., & Friedland, G. (2019). Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. The Lancet HIV, 6(3), e201-e204. https://doi.org/10.1016/S2352-3018(19)30035-9

Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. / O'Donnell, Max R.; Padayatchi, Nesri; Daftary, Amrita; Orrell, Catherine; Dooley, Kelly Elise; Rivet Amico, K.; Friedland, Gerald.

In: The Lancet HIV, Vol. 6, No. 3, 01.03.2019, p. e201-e204.

Research output: Contribution to journalComment/debate

O'Donnell, MR, Padayatchi, N, Daftary, A, Orrell, C, Dooley, KE, Rivet Amico, K & Friedland, G 2019, 'Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection' The Lancet HIV, vol. 6, no. 3, pp. e201-e204. https://doi.org/10.1016/S2352-3018(19)30035-9
O'Donnell, Max R. ; Padayatchi, Nesri ; Daftary, Amrita ; Orrell, Catherine ; Dooley, Kelly Elise ; Rivet Amico, K. ; Friedland, Gerald. / Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection. In: The Lancet HIV. 2019 ; Vol. 6, No. 3. pp. e201-e204.
@article{3e0390b237db44caa622fec6e167ea59,
title = "Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection",
abstract = "Bedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved survival including in HIV patients with multidrug and extensively drug-resistant tuberculosis. In line with WHO recommendations, in South Africa and other low-income and middle-income settings, antiretroviral therapy is switched from generic fixed-dose combination efavirenz-containing regimens to twice-daily nevirapine with separate companion pills because of interactions between efavirenz and bedaquiline. Early data suggest a signal for low antiretroviral therapy adherence after this antiretroviral therapy switch. Mortality and other tuberculosis-specific benefits noted with bedaquiline treatment in multidrug and extensively drug-resistant tuberculosis HIV might be compromised by HIV viral failure, and emergent antiretroviral resistance. Programmatic responses, such as adherence support and dual pharmacovigilance, should be instituted; antiretroviral therapy initiation with fixed-dose combinations without bedaquiline drug interactions should be strongly considered.",
author = "O'Donnell, {Max R.} and Nesri Padayatchi and Amrita Daftary and Catherine Orrell and Dooley, {Kelly Elise} and {Rivet Amico}, K. and Gerald Friedland",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/S2352-3018(19)30035-9",
language = "English (US)",
volume = "6",
pages = "e201--e204",
journal = "The Lancet HIV",
issn = "2352-3018",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection

AU - O'Donnell, Max R.

AU - Padayatchi, Nesri

AU - Daftary, Amrita

AU - Orrell, Catherine

AU - Dooley, Kelly Elise

AU - Rivet Amico, K.

AU - Friedland, Gerald

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Bedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved survival including in HIV patients with multidrug and extensively drug-resistant tuberculosis. In line with WHO recommendations, in South Africa and other low-income and middle-income settings, antiretroviral therapy is switched from generic fixed-dose combination efavirenz-containing regimens to twice-daily nevirapine with separate companion pills because of interactions between efavirenz and bedaquiline. Early data suggest a signal for low antiretroviral therapy adherence after this antiretroviral therapy switch. Mortality and other tuberculosis-specific benefits noted with bedaquiline treatment in multidrug and extensively drug-resistant tuberculosis HIV might be compromised by HIV viral failure, and emergent antiretroviral resistance. Programmatic responses, such as adherence support and dual pharmacovigilance, should be instituted; antiretroviral therapy initiation with fixed-dose combinations without bedaquiline drug interactions should be strongly considered.

AB - Bedaquiline, a potent new therapy for drug-resistant tuberculosis, results in improved survival including in HIV patients with multidrug and extensively drug-resistant tuberculosis. In line with WHO recommendations, in South Africa and other low-income and middle-income settings, antiretroviral therapy is switched from generic fixed-dose combination efavirenz-containing regimens to twice-daily nevirapine with separate companion pills because of interactions between efavirenz and bedaquiline. Early data suggest a signal for low antiretroviral therapy adherence after this antiretroviral therapy switch. Mortality and other tuberculosis-specific benefits noted with bedaquiline treatment in multidrug and extensively drug-resistant tuberculosis HIV might be compromised by HIV viral failure, and emergent antiretroviral resistance. Programmatic responses, such as adherence support and dual pharmacovigilance, should be instituted; antiretroviral therapy initiation with fixed-dose combinations without bedaquiline drug interactions should be strongly considered.

UR - http://www.scopus.com/inward/record.url?scp=85062244059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062244059&partnerID=8YFLogxK

U2 - 10.1016/S2352-3018(19)30035-9

DO - 10.1016/S2352-3018(19)30035-9

M3 - Comment/debate

VL - 6

SP - e201-e204

JO - The Lancet HIV

JF - The Lancet HIV

SN - 2352-3018

IS - 3

ER -